Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 23, 2019 01:51 ET | Source: Curetis

Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens

- Final LRT BAL panel demonstrates overall weighted average sensitivity of up to 94.7% and overall weighted average specificity of up to 98.4% - Unyvero provides results after approximately five...
July 04, 2019 02:02 ET | Source: Curetis

Curetis Group Company Ares Genetics is Granted Key European Patent on Genetic Resistance Testing

Curetis Group Company Ares Genetics is Granted Key European Patent on Genetic Resistance Testing Patent broadly covers genetic biomarkers and biomarker combinations indicating antibiotic...
July 02, 2019 02:00 ET | Source: Curetis

Curetis To Attend Key Conferences in the Third Quarter of 2019

Amsterdam, the Netherlands, and Holzgerlingen, Germany, July 2, 2019, 08:00 am CET - Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular...
June 28, 2019 01:59 ET | Source: Curetis

Curetis Reports Results of the Annual General Meeting Held on June 27, 2019

- All proposed AGM resolutions approved by shareholders Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, June 28, 2019, 08:00 am CEST / 02:00 am EDT - Curetis N.V. (the...
June 04, 2019 02:11 ET | Source: Curetis

New Data on Curetis’ Unyvero LRT Panel for Pneumonia to be Presented at ASM Microbe 2019

- Several scientific conference contributions outline benefits of U.S. FDA-cleared Unyvero LRT Application Cartridge in both endotracheal aspirate and bronchoalveolar lavage samples - Study shows...
May 23, 2019 02:00 ET | Source: Curetis

Curetis Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples

- Test shows overall weighted average sensitivity of 90.1% (94.7%) and overall weighted average specificity of 98.4% (97.9%) in prospective (retrospective) sample cohort - U.S. FDA 510(k)...
May 21, 2019 00:55 ET | Source: Curetis

Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville

- Curetis and EIB agree on equity-linked participation upon maturity of new EUR 5 million tranche of debt financing - Yorkville to provide funding of EUR 1.5 million to Curetis Amsterdam, the...
May 17, 2019 01:00 ET | Source: Curetis

Curetis Announces Financial Results for the First Three Months of 2019

Curetis Announces Financial Results for the First Three Months of 2019 - Total year-on-year revenue growth of approximately 45% - Successful implementation of corporate re-organization and...
May 15, 2019 08:00 ET | Source: Curetis

Curetis to Hold Annual General Shareholders’ Meeting on June 27, 2019

Curetis to Hold Annual General Shareholders’ Meeting on June 27, 2019 Amsterdam, the Netherlands, Holzgerlingen, Germany and San Diego, CA, USA, May 15, 2019, 02:00 pm CEST / 08:00 am EDT - Curetis...
April 12, 2019 02:00 ET | Source: Curetis

Press release: Curetis’ Subsidiary Ares Genetics Introduces NGS Services for Pharma and Public Health Sector at Upcoming ECCMID 2019

Strain-typing and AMR detection of clinical isolates based on ARESdbSet-up of own NGS service laboratory in Vienna, Austria Vienna, Austria, Holzgerlingen, Germany, and Amsterdam, The...